The expanded facility will focus on manufacturing therapeutic antibody drugs, contributing to the delivery of breakthrough treatments to patients globally. This investment reflects Novartis' commitment to advancing the biopharmaceutical sector and meeting the increasing demand for biologics.

Mr. Heng Swee Keat, Deputy Prime Minister and Coordinating Minister for Economic Policies, highlighted Singapore's role as a key player in the global biomedical landscape. He emphasized the importance of innovation and collaboration in driving the sector's growth and delivering innovative biologic products to combat diseases.

Steffen Lang, President of Operations at Novartis, emphasized the growing significance of biotherapeutics in addressing unmet medical needs. The new facility, expected to be operational by early 2026, will strengthen Novartis' biopharmaceutical manufacturing and supply chain across Asia while enhancing local capabilities and talent development in Singapore.

The expansion project is set to create 100 high-skilled job opportunities, contributing to the growth of Singapore's life science industry. Novartis recognizes the importance of investing in talent and plans to provide training for both new hires and existing employees to thrive in a digitalized and automated manufacturing environment.

The groundbreaking event was graced by DPM Heng Swee Keat as the Guest-of-Honour, along with Frank Grütter, Swiss Ambassador to Singapore, and Ms. Cindy Koh, Executive Vice President of the Economic Development Board (EDB).

Novartis has maintained a strong partnership with Singapore since 1986, with investments totaling more than US$1 billion. The expansion of its manufacturing capabilities underscores Novartis' commitment to Singapore's pharmaceutical sector and its dedication to advancing healthcare innovation on a global scale.